• 1
    Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51F58.
  • 2
    Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100: 700705.
  • 3
    Behrens G, Dejam A, Schmidt H et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63F70.
  • 4
    Noor MA, Seneviratne T, Aweeka FT et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16: F1F8.
  • 5
    Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130139.
  • 6
    Menotti A, Keys A, Blackburn H et al. Comparison of multivariate predictive power of major risk factors for coronary heart diseases in different countries: results from eight nations of the Seven Countries Study, 25-year follow-up. J Cardiovasc Risk 1996; 3: 6975.
  • 7
    Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 18371847.
  • 8
    Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 1990; 322: 16351641.
  • 9
    Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351: 1959.
  • 10
    Holmberg SD, Moorman AC, Williamson JM et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 17471748.
  • 11
    Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 24792486.
  • 12
    The DAD Study GTroup. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 19932003.
  • 13
    Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471477.
  • 14
    Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293298.
  • 15
    Currier JS, Taylor A, Boyd F et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506512.
  • 16
    Dong KL, Bausserman LL, Flynn MM et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 1999; 21: 107113.
  • 17
    Saves M, Chene G, Ducimetiere P et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37: 292298.
  • 18
    Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 24862497.
  • 19
    De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 16011610.
  • 20
    Faergeman O. New British recommendations for prevention of coronary heart disease in clinical practice. Heart 1999; 81: 335.
  • 21
    Lauer MS, Fontanarosa PB. Updated guidelines for cholesterol management. J Am Med Assoc 2001; 285: 25082509.
  • 22
    Ramsay LE, Wallis EJ, Haq IU, Yeo WW, Jackson PR. Drug therapy for coronary heart disease: the Sheffield table. Lancet 1998; 351: 443444.
  • 23
    Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 11791193.
  • 24
    Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583612.
  • 25
    D:A:D Coordinating Centre. Data Collection on Adverse Events of Anti-HIV Drugs; Study Documents.
  • 26
    WHO. MONICA Project. MONICA Manual, Part IV, Event Registration . http:/
  • 27
    Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med 1984; 311: 11441147.
  • 28
    Law M, Friis-Møller N, Weber R et al. Modelling the three year risk of myocardial infarction among participants in the DAD study. HIV Med 2003; 4: 110.
  • 29
    Little R, Rubin D. Statistical Analysis with Missing Data. New York: John Wiley & Sons, 1987.
  • 30
    Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229234.
  • 31
    Pekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 17001707.
  • 32
    Rosengren A, Hagman M, Wedel H, Wilhelmsen L. Serum cholesterol and long-term prognosis in middle aged men with myocardial infarction and angina pectoris: a 16-year follow-up of the Primary Prevention Study in Goteburg, Sweden. Eur Heart J 1997; 18: 754761.
  • 33
    World Health Organisation (WHO). 1997–1999 World Health Statistics Annual.
  • 34
    Efron B. An Introduction to the Bootstrap. New York: Chapman & Hall, 1993.
  • 35
    Thomsen TF, Davidsen M, Ibsen H, Jorgensen T, Jensen G, Borch-Johnsen K. A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Coopenhagen Risk Score. J Cardiocascular Risk 2001; 8: 291297.
  • 36
    Empana JP, Ducimetiere P, Arveiler D et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 2003; 24: 19031911.
  • 37
    De Visser CL, Bilo HJ, Thomsen TF, Groenier KH, Meyboom-de Jong B. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med 2003; 253: 553562.
  • 38
    Thomsen TF, McGee D, Davidsen M, Jorgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002; 31: 817822.
  • 39
    Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 15471557.
  • 40
    Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29: 441449.
  • 41
    Larsen CT, Dahlin J, Blackburn H et al. Prevalence and prognosis of electrocardiographic left ventricular hypertrophy, ST segment depression and negative T-wave; the Copenhagen City Heart Study. Eur Heart J 2002; 23: 315324.
  • 42
    Doser N, Kubli S, Telenti A et al. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. AIDS 2002; 16: 19821983.
  • 43
    Baldini F, Di Giambenedetto S, Cingolani A, Murri R, Ammassari A, De Luca A. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. AIDS 2000; 14: 16601662.
  • 44
    Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 2003; 91: 4B8B.
  • 45
    Aberg JA. Cardiovascular risk among HIV-positive patients on antiretroviral therapy. J Int Assoc Physicians AIDS Care (Chic III) 2003; 2 (Suppl. 2): S24S39.
  • 46
    Kuulasmaa K, Tunstall-Pedoe H, Dobson A et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000; 355: 675687.
  • 47
    Menotti A, Lanti M, Puddu PE, Kromhout D. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart 2000; 84: 238244.
  • 48
    Dube MP, Stein JH, Aberg JA et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37: 613627.